[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"splenectomy-status\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:splenectomy-status":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,50,69,88,106,137,167,194,215,232,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100640414","effect-of-lsd-on-renal-function-in-cirrhosis-patients-with-portal-hypertension-bleeding-2-year-follow-up-100640414",false,"NCT07585786","Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Renal Function in Patients With Liver Cirrhosis, Portal Hypertension Bleeding","LSD-RFPH","Inclusion Criteria:\n\n1. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n2. Splenomegaly and hypersplenism\n3. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n4. Age 18-80 years, male or female\n5. Child-Pugh Class A or B liver function\n6. No history of primary renal disease or acute kidney injury (AKI)\n7. Signed written informed consent\n8. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)\n3. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection\n4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n5. Hepatic encephalopathy or refractory ascites within 1 month before surgery\n6. Pregnancy or lactation\n7. Poor compliance, inability to complete follow-up","ALL","18 Years","80 Years",{"count":21,"type":22},30,"ESTIMATED","2 Years","OBSERVATIONAL","Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .",[27,28,29,30],"Cirrhosis, Liver","Splenectomy; Status","Renal Function Abnormal","Portal Hypertension",[32,33,34,35,36,37],"Cirrhosis","Splenectomy","Laparoscopy","azygoportal disconnection","Renal function","Portal hypertension bleeding","NOT_YET_RECRUITING","2026-05-14",{"date":41,"type":42},"2026-05-18","ACTUAL",{"date":44,"type":22},"2026-05-01",{"date":46,"type":22},"2029-02-28",{"name":48,"class":49},"Northern Jiangsu People's Hospital","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":58,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":67,"locationsCount":68},"100639931","effect-of-laparoscopic-splenectomy-on-renal-function-in-cirrhotic-patients-with-hypersplenism-2-year-follow-up-100639931","NCT07585773","Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Short-Term and Long-Term (2-Year) Effects of Laparoscopic Splenectomy on Renal Function in Patients With Liver Cirrhosis, Splenomegaly and Hypersplenism","LS-RF","Inclusion Criteria:\n\n1. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n2. Splenomegaly and hypersplenism\n3. No history of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n4. Age 18-80 years, male or female\n5. Child-Pugh Class A or B liver function\n6. No history of primary renal disease or acute kidney injury (AKI)\n7. Signed written informed consent\n8. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)\n3. Previous abdominal surgery precluding safe laparoscopic splenectomy\n4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n5. Cirrhotic complications (portal hypertension bleeding, hepatic encephalopathy, refractory ascites) within 1 month before surgery\n6. Pregnancy or lactation\n7. Poor compliance, inability to complete follow-up",{"count":21,"type":22},"Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether laparoscopic splenectomy can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .",[32,28,61,62],"Hypersplenism","Kidney Function Issue",[32,30,33,34,61],{"date":41,"type":42},{"date":44,"type":22},{"date":46,"type":22},{"name":48,"class":49},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":77,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":87,"locationsCount":68},"100639930","effect-of-laparoscopic-splenectomy-on-lipid-profiles-in-cirrhotic-patients-with-hypersplenism-2-year-follow-up-100639930","NCT07588373","Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Short-Term and Long-Term (2-Year) Effects of Laparoscopic Splenectomy on Lipid Profiles in Patients With Liver Cirrhosis, Splenomegaly and Hypersplenism","LS-LP-CH","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n3. Splenomegaly and hypersplenism\n4. Child-Pugh Class A or B liver function\n5. Signed written informed consent\n6. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. No history of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n3. Previous abdominal surgery precluding safe laparoscopic splenectomy.\n4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n5. Metabolic\u002Fendocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.\n6. Infections\u002Finflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases.\n7. Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery\n8. Pregnancy or lactation\n9. Poor compliance, inability to complete follow-up",{"count":21,"type":22},"Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing laparoscopic splenectomy to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether laparoscopic splenectomy can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.",[32,28,61,80],"Lipid Profiles",[32,33,34,80,61,82],"portal hypertension","2026-05-10",{"date":39,"type":42},{"date":44,"type":22},{"date":46,"type":22},{"name":48,"class":49},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":96,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":105,"locationsCount":68},"100638416","effect-of-lsd-on-lipid-profiles-in-cirrhosis-patients-with-portal-hypertension-bleeding-2-year-follow-up-100638416","NCT07588334","Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Lipid Profiles in Patients With Liver Cirrhosis, Portal Hypertension Bleeding.","LSD-LPPH","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n3. Splenomegaly and hypersplenism\n4. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n5. Child-Pugh Class A or B liver function\n6. Signed written informed consent\n7. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection\n3. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n4. Metabolic\u002Fendocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.\n5. Infections\u002Finflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases.\n6. Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery\n7. Pregnancy or lactation\n8. Poor compliance, inability to complete follow-up",{"count":21,"type":22},"Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.",[27,28,30,80],[32,33,34,80,35,100,101],"Portal Hypertension Bleeding","hypersplenism",{"date":39,"type":42},{"date":44,"type":22},{"date":46,"type":22},{"name":48,"class":49},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":68},"100625851","development-of-an-italian-questionnaire-for-splenectomized-patients-using-a-delphi-consensus-method-100625851","NCT07428005","Development of an Italian Questionnaire for Splenectomized Patients Using a Delphi Consensus Method","Development of an Italian Questionnaire to Assess Awareness and Knowledge of Infectious Risk Prevention Strategies in Splenectomized Patients Using a Delphi Consensus Method","Inclusion Criteria:\n\n* Healthcare professionals working at Fondazione Policlinico Universitario A. Gemelli IRCCS\n* Professional experience in vaccination or infection prevention\n* Clinical involvement in care of patients with asplenia or related conditions\n* Italian native language proficiency\n* Provision of informed consent\n\nExclusion Criteria:\n\n* Participation in the expert panel is restricted to individuals who meet all predefined inclusion criteria. Failure to satisfy any inclusion criterion automatically results in exclusion from the study population",true,{"count":115,"type":22},20,"This study aims to develop an Italian-language questionnaire assessing awareness, knowledge of infectious risk prevention strategies, and vaccination attitudes among splenectomized individuals. The questionnaire will be developed through a structured Delphi consensus process involving a multidisciplinary panel of healthcare professionals experienced in infection prevention and vaccination strategies. Two Delphi rounds will be conducted online to evaluate item relevance and clarity. Items reaching predefined consensus thresholds will be included in the final questionnaire. The resulting tool will support future studies assessing preventive care awareness and vaccination uptake among splenectomized patients.",[28,118,119],"Asplenia","Splenectomized Patients",[121,122,123,124,125,126],"splenectomy","asplenia","vaccination","infection prevention","delphi study","questionnaire development","RECRUITING","2026-04-02",{"date":130,"type":42},"2026-04-08",{"date":132,"type":42},"2026-01-01",{"date":134,"type":22},"2026-04-01",{"name":136,"class":49},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":147,"studyType":24,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100620228","evaluation-of-the-effectiveness-of-an-educational-intervention-in-splenectomized-patients-100620228","NCT07354893","Evaluation of the Effectiveness of an Educational Intervention in Splenectomized Patients","Evaluation of an Educational Intervention on Knowledge and Awareness of Infectious Risk in Splenectomized Patients and on Their Satisfaction With Vaccination Management in an Intra-hospital Outpatient Setting.","SPLE-VAC","Inclusion Criteria:\n\n* Adult patients (≥18 years old)\n* Patients splenectomized at FPG for whom a vaccination consultation is requested during hospitalization\n* Patients who provide signed informed consent to participate in the study and for the processing of personal data for research purposes\n\nExclusion Criteria:\n\n* Minor patients\n* Lack of signed informed consent for participation in the study and for the processing of personal data for research purposes\n* Patients splenectomized at other healthcare facilities",{"count":146,"type":22},100,"24 Months","The absence or dysfunction of the spleen is associated with a substantially increased risk of invasive infections that may rapidly progress to fulminant sepsis, including overwhelming post-splenectomy infection (OPSI), a medical emergency with high mortality. Although the risk is greatest in the first two years after splenectomy, it persists lifelong. Preventing infections in patients with anatomical or functional asplenia requires an integrated strategy that includes patient education, early recognition of symptoms, behavioral measures, antibiotic prophylaxis when indicated, and vaccination.\n\nPost-splenectomy immunization has been shown to reduce OPSI incidence. Regional and international guidelines recommend vaccination against pneumococcus, Haemophilus influenzae type b, meningococcus (B and ACWY), herpes zoster, diphtheria-tetanus-pertussis, measles-mumps-rubella-varicella, and annual influenza. However, adherence to these recommendations is frequently suboptimal, often due to limited awareness among patients and healthcare professionals.\n\nThis study involves the intra-hospital vaccination team providing structured vaccination consultations to splenectomized patients hospitalized at the Fondazione Policlinico Universitario \"A. Gemelli\" IRCCS. During ward consultations, patients receive an educational intervention on asplenia-related infectious risks and preventive measures, supported by standardized informational materials. Effectiveness is evaluated using a pre-post questionnaire assessing knowledge and awareness. Patients completing the vaccination pathway at the outpatient clinic also complete a questionnaire assessing their experience with vaccination management in an intra-hospital setting.",[119,33,28,118],[151,152,153,154,155,122,121,156,157],"OPSI","infection risk","Infection Prevention","Preventive measures","Vaccination","splenectomized patients","post splenectomy infections","2026-01-29",{"date":160,"type":42},"2026-02-02",{"date":162,"type":42},"2026-01-13",{"date":164,"type":22},"2028-01-13",{"name":136,"class":49},2,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":176,"phases":177,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":68},"100608739","laparoscopic-partial-splenectomy-for-hypersplenism-in-liver-cirrhosis-patients-100608739","NCT07205471","Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients","The Clinical Efficacy of Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients","LPSH","Inclusion Criteria:\n\n* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology\n* Splenomegaly with secondary hypersplenism\n* gastroesophageal variceal bleeding\n* Informed consent to participate in the study\n\nExclusion Criteria:\n\n* Hepatocellular carcinoma or any other malignancy,\n* Child-Pugh grade C\n* Recent peptic ulcer disease\n* History of Hemorrhagic stroke\n* Pregnancy.\n* Uncontrolled Hypertension\n* Human immunodeficiency virus (HIV) infection",{"count":21,"type":22},"INTERVENTIONAL",[178],"NA","In this study,the researchers compared the changes in immune function-related indicators in patients with liver cirrhosis following laparoscopic partial splenectomy,to determine whether this surgical intervention can enhance postoperative immune function and thereby improve patient outcomes.",[181,28,182],"Cirrhoses, Liver","Partial",[32,33,34,184,185],"immune function","partial","2025-09-25",{"date":188,"type":42},"2025-10-03",{"date":190,"type":42},"2025-09-24",{"date":192,"type":22},"2028-09-24",{"name":48,"class":49},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":176,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":68},"100465252","the-effect-of-laparoscopic-splenectomy-and-azygoportal-disconnection-on-the-immune-function-for-cirrhosis-patients-100465252","NCT05338294","The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients","ELSDI",{"count":115,"type":22},[178],"In this study, the investigators compared the improvement of immune function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative immune function and improve patient prognosis.",[27,28],[32,33,34,205,206],"Immune function","Azygoportal disconnection","2025-05-26",{"date":209,"type":42},"2025-05-28",{"date":211,"type":42},"2022-03-01",{"date":213,"type":22},"2025-07-31",{"name":48,"class":49},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":176,"phases":222,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":230,"leadSponsor":231,"locationsCount":68},"100464264","the-effect-of-laparoscopic-splenectomy-and-azygoportal-disconnection-on-liver-reserve-function-for-cirrhosis-patients-100464264","NCT05325437","The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients","ELSDL",{"count":115,"type":22},[178],"In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative liver reserve function and improve patient prognosis.",[27,28,30],[32,33,206,34,226],"Liver Reserve Function",{"date":228,"type":42},"2025-05-30",{"date":211,"type":42},{"date":213,"type":22},{"name":48,"class":49},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":176,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":247,"locationsCount":68},"100464263","the-effect-of-laparoscopic-splenectomy-on-liver-reserve-function-for-cirrhosis-patients-100464263","NCT05325424","The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients","ELSL","Inclusion Criteria:\n\n* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology\n* Splenomegaly with secondary hypersplenism, Platelet count \\\u003C 50\\*10\\^9\u002FL\n* Informed consent to participate in the study\n\nExclusion Criteria:\n\n* Hepatocellular carcinoma or any other malignancy,\n* Child-Pugh grade C\n* Recent peptic ulcer disease\n* History of Hemorrhagic stroke\n* Pregnancy.\n* Uncontrolled Hypertension\n* Bleeding portal hypertension\n* Human immunodeficiency virus (HIV) infection",{"count":115,"type":22},[178],"In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy. To determine whether surgical treatment can help enhance postoperative liver reserve function and improve patient prognosis.",[27,28],[32,33,226,34],{"date":228,"type":42},{"date":211,"type":42},{"date":213,"type":22},{"name":48,"class":49},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":113,"sex":17,"minAge":18,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":176,"phases":258,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":68},"100518049","phase-2-meningococcal-b-vaccine-in-patients-with-asplenia-100518049","NCT06025487","Meningococcal B Vaccine in Patients with Asplenia","Immunogenicity and Safety of a Meningococcal Serogroup B Vaccine in Adult Patients with Asplenia","Inclusion Criteria:\n\nFor asplenic patients:\n\n* asplenia due to splenectomy or functional asplenia\n* 18 to 60 years of age\n* if female: have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study\n* providing written informed consent\n\nFor healthy controls:\n\n* 18 to 60 years of age\n* if female: have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study\n* providing written informed consent\n\nExclusion Criteria:\n\nFor asplenic patients:\n\n* pregnant or lactating\n* febrile illness within last two weeks prior to enrolment\n* allergic reactions to vaccination in past\n* chemotherapy with Rituximab within last six months or during study period\n* more than 20mg prednisone per day within last four weeks prior or at the time of enrolment\n* previous vaccination against meningococcal serogroup B\n\nFor healthy controls:\n\n* pregnant or lactating\n* febrile illness within last two weeks prior to enrolment\n* allergic reactions to vaccination in past\n* any immunosuppressive condition or medication\n* previous vaccination against meningococcal serogroup B","60 Years",{"count":257,"type":22},80,[259],"PHASE2","Patients without a spleen (asplenia) experience an increased risk for septicaemia from encapsulated bacteria, which is associated with a high mortality rate. Meningococcal bacteria can cause such infections and serogroup B is the dominant meningococcal subtype in Europe. Therefore, vaccination for risk populations like patients without a spleen is a pressing matter. Considering the effectiveness of the meningococcal serogroup B vaccine, data for this high-at-risk population is currently lacking. The aim of this study is to evaluate the meningococcal B vaccine (BEXSERO®) in patients without a spleen compared to a healthy control group. A total of 40 patients and 40 healthy persons will receive a two-dose schedule of BEXSERO® with a one-month interval between doses. The effectiveness of the vaccine will be determined by measuring antibodies against different meningococcal strains in the blood of the patient. The amount of antibodies one month after second vaccination will be compared between patients and healthy persons. The most reliable assay to determine antibodies against meningococcal strains is the human serum bactericidal assay which will be carried out in a reference laboratory. Other end points are the persistence of antibodies after six months and the cellular immune response. The cellular immune response will be assessed by measuring the proliferation of certain immune cells like lymphocytes and the amount of produced cytokines (signalling proteins) after vaccination. In addition, the safety of the vaccine will be evaluated by documenting all adverse reactions to the vaccine. Overall, this study will be the first to assess the effectiveness of the meningococcal B vaccine in this high-at-risk population and provide data for vaccination guidelines.",[28],[118,263,264],"Meningococcal disease","Meningococcal B vaccine","2024-11-19",{"date":267,"type":42},"2024-11-22",{"date":269,"type":42},"2024-03-12",{"date":271,"type":22},"2025-12-31",{"name":273,"class":49},"Medical University of Vienna"]